WF
ForwardVue Pharma develops novel therapeutics to reduce the treatment burden for patients with retinal diseases. The company is focused on a patent-protected, long-acting ORAI1 blocker administered via intravitreal injection for up to 12 months. This platform targets retinal neovascular disease by acting both upstream and downstream of existing VEGF inhibition treatments.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- ForwardVue Pharma develops novel therapeutics to reduce the treatment burden for patients with retinal diseases. The company is focused on a patent-protected, long-acting ORAI1 blocker administered via intravitreal injection for up to 12 months. This platform targets retinal neovascular disease by acting both upstream and downstream of existing VEGF inhibition treatments.